张阳,曾勇

• 1:首都医科大学附属北京安贞医院心内科北京市心肺血管疾病研究所

摘要(Abstract)：

<正>急性冠状动脉综合征(acute coronary syndrome,ACS)是一类严重的心血管疾病,多发生在冠状动脉粥样硬化斑块狭窄的基础上,不稳定斑块糜烂、破裂继发血栓形成,从而阻塞冠状动脉内血流,导致相应供血区域心肌出现缺

关键词(KeyWords)： 经皮冠状动脉介入治疗;血栓抽吸;冠状动脉微循环障碍

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 张阳,曾勇

参考文献(References)：

• [1] Timmis A. Acute coronary syndromes. BMJ, 2015, 351:h5153.
• [2] Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med, 2006, 3(9):499-506.
• [3] Bekkers SC, Yazdani SK, Virmani R, et al. Microvascular obstruction:underlying pathophysiology and clinical diagnosis. J Am Coll Cardiol,2010, 55(16):1649-1660.
• [4] Yip HK, Chen MC, Chang HW, et al. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction:predictors of slow-flow and no-reflow phenomenon. Chest, 2002, 122(4):1322-1332.
• [5]欧洋，沈伟，施海明.经皮冠状动脉介入治疗相关冠状动脉微循环障碍的研究进展.中国介入心脏病学杂志，2019, 27(7):400-403.
• [6] Henriques JP, Zijlstra F, Ottervanger JP, et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. Eur Heart J, 2002, 23(14):1112-1117.
• [7] Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol, 2010,55(21):2383-2389.
• [8] Sardella G, Mancone M, Bucciarelli-Ducci C, et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size:the EXPIRA(thrombectomy with export catheter in infarct-related artery during primary percutaneous coronary intervention)prospective, randomized trial. J Am Coll Cardiol, 2009, 53(4):309-315.
• [9] Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med,2008, 358(6):557-567.
• [10] Frobert O, Lagerqvist B, Olivecrona GK, et al. Thrombus aspiration during ST-segment elevation myocardial infarction. N Engl J Med,2013, 369(17):1587-1597.
• [11] Lagerqvist B, Frobert O, Olivecrona GK, et al. Outcomes 1 year after thrombus aspiration for myocardial infarction. N Engl J Med,2014, 371(12):1111-1120.
• [12] Jolly SS, Cairns JA, Yusuf S, et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med,2015, 372(15):1389-1398.
• [13] Jolly SS, Cairns JA, Yusuf S, et al. Outcomes after thrombus aspiration for ST elevation myocardial infarction:1-year followup of the prospective randomised TOTAL trial. Lancet, 2016, 387(10014):127-135.
• [14] Jolly SS, Cairns JA, Lavi S, et al. Thrombus Aspiration in patients with high thrombus burden in the TOTAL trial. J Am Coll Cardiol,2018, 72(14):1589-1596.
• [15] Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction. The JETSTENT trial. J Am Coll Cardiol, 2010, 56(16):1298-1306.
• [16] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC). Eur Heart J, 2018, 39(2):119-177.
• [17]中国医师协会心血管内科医师分会冠状动脉血栓抽吸共识专家组.冠状动脉血栓抽吸临床应用专家共识.中华医学杂志，2017, 97(21):1624-1632.
• [18] Neumann FJ, Blasini R, Schmitt C, et al. Eff ect of glycoproteinⅡb/Ⅲa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation, 1998, 98(24):2695-2701.
• [19] De Luca G, Navarese E, Marino P. Risk profile and benefits from GpⅡb-Ⅲa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty:a metaregression analysis of randomized trials. Eur Heart J, 2009, 30(22):2705-2713.
• [20] Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction:the INFUSE-AMI randomized trial.JAMA, 2012, 307(17):1817-1826.
• [21] Thiele H, W?hrle J, Hambrecht R, et al. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction:a randomised trial. Lancet, 2012, 379(9819):923-931.
• [22] Desch S, Wohrle J, Hambrecht R, et al. Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction:1-year results of the randomized AIDA STEMI trial. J Am Coll Cardiol, 2013, 62(13):1214-1215.
• [23] Piccolo R, Eitel I, Iversen AZ, et al. Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction:a pooled analysis of individual patient data from five randomised controlled trials. EuroIntervention, 2014, 9(9):1110-1120.
• [24] Piccolo R, Eitel I, Galasso G, et al. 1-year outcomes with intracoronary Abciximab in diabetic patients undergoing primary percutaneous coronary intervention. J Am Coll Cardiol, 2016, 68(7):727-738.
• [25] Zhu TQ, Zhang Q, Qiu JP, et al. Beneficial eff ects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention:the ICTAMI study. Int J Cardiol, 2013, 165(3):437-443.
• [26] Sun Z, Zeng J, Huang H. Intracoronary injection of tirofiban prevents microcirculation dysfunction during delayed percutaneous coronary intervention in patients with acute myocardial infarction.Int J Cardiol, 2016, 208:137-140.
• [27] Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation, 2006, 114(10):1070-1077.
• [28] Lupi A, Rognoni A, Cavallino C, et al. Intracoronary vs intravenous bivalirudin bolus in ST-elevation myocardial infarction patients treated with primary angioplasty. Eur Heart J Acute Cardiovasc Care, 2016, 5(5):487-496.
• [29] Sezer M, Oflaz H, G?ren T, et al. Intracoronary streptokinase after primary percutaneous coronary intervention. N Engl J Med, 2007,356(18):1823-1834.
• [30] McCartney PJ, Eteiba H, Maznyczka AM, et al. Eff ect of lowdose intracoronary Alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction:a randomized clinical trial. JAMA, 2019,321(1):56-68.
• [31] Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol, 1989, 63(21):18J.
• [32] Shi L, Chen L, Qi G, et al. Eff ects of intracoronary nicorandil on myocardial microcirculation and clinical outcomes in patients with acute myocardial infarction:a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs, 2020, 20(2):191-198.
• [33] Polimeni A, De Rosa S, Sabatino J, et al. Impact of intracoronary adenosine administration during primary PCI:A meta-analysis. Int J Cardiol, 2016, 203:1032-1041.
• [34] Zhao S, Qi G, Tian W, et al. Eff ect of intracoronary nitroprusside in preventing no reflow phenomenon during primary percutaneous coronary intervention:a meta-analysis. J Interv Cardiol, 2014, 27(4):356-364.
• [35] Huang D, Qian J, Ge L, et al. Restoration of coronaryflow in patients with no-reflow after primary coronary intervention of acute myocardial infarction(RECOVER). Am Heart J, 2012, 164(3):394-401.
• [36] Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute STsegment elevation myocardial infarction:a randomized controlled trial. JAMA, 2005, 293(9):1063-1072.
• [37] Haeck JDE, Koch KT, Bilodeau L, et al. Randomized comparison of primary percutaneous coronary intervention with combined proximal embolic protection and thrombus aspiration versus primary percutaneous coronary intervention alone in ST-segment elevation myocardial infarction:the PREPARE(proximal embolic protection in acute myocardial infarction and resolution of ST-elevation)study.JACC Cardiovasc Interv, 2009, 2(10):934-943.
• [38] Teramoto R, Sakata K, Miwa K, et al. Impact of distal protection with filter-type device on long-term outcome after percutaneous coronary intervention for acute myocardial infarction:clinical results withfiltrap. J Atheroscler Thromb, 2016, 23(12):1313-1323.
• [39] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J, 2019, 40(2):87-165.
• [40] Heusch G, B?tker HE, Przyklenk K, et al. Remote ischemic conditioning. J Am Coll Cardiol, 2015, 65(2):177-195.
• [41] Zografos TA, Katritsis GD, Tsiafoutis I, et al. Eff ect of one-cycle remote ischemic preconditioning to reduce myocardial injury during percutaneous coronary intervention. Am J Cardiol, 2014, 113(12):2013-2017.
• [42]曾凯东，谢莲娜，刘灿章，等.肢体远隔缺血适应对成功行经皮冠状动脉介入治疗ST段抬高型心肌梗死患者冠状动脉微循环灌注及血清亚硝酸盐水平的影响.中国介入心脏病学杂志，2018, 26(11):632-637.
• [43] Badr S, Ben-Dor I, Dvir D, et al. The state of the excimer laser for coronary intervention in the drug-eluting stent era. Cardiovasc Revasc Med, 2013, 14(2):93-98.
• [44]于一，赵迎新，史冬梅，等.准分子激光在经桡动脉复杂冠状动脉病变介入治疗中的应用.中国介入心脏病学杂志，2016, 24(10):587-591.
• [45]谢洪祥，邓仕华，黄磊，等.延迟支架置入在高血栓负荷急性ST段抬高型心肌梗死患者中的应用.实用医学杂志，2017, 33(11):1791-1794.
• [46] Cuisset T, Hamilos M, Melikian N, et al. Direct stenting for stable angina pectoris is associated with reduced periprocedural microcirculatory injury compared with stenting after pre-dilation. J Am Coll Cardiol, 2008, 51(11):1060-1065.